RxDoctor Payments Data

Chellee Furbert

Psychiatric/Mental Health · North Smithfield, RINPI 1609358753

Payments from drug & device makers

$447in general payments, 2019–2025

Across 15 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$121
  • AbbVie$120
  • Paratek Pharmaceuticals, Inc.$85
  • Boston Scientific$44
  • Ironshore Pharmaceuticals Inc.$30
  • Angiodynamics, Inc.$17
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$447 in reported general payments places this provider in the 45th percentile of 196 psychiatric/mental health providers in Rhode Island.

See all psychiatric/mental health providers in Rhode Island

Medicare billing

Part B allowed, 2024
$27,905
Medicare patients
34
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl32$43,832
Aripiprazole161$6,255
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine193$4,442
Quetiapine Fumarate210$3,844
Clonazepam308$3,220
Lurasidone Hcl22$2,883
Trazodone Hcl220$2,793
Bupropion XlBupropion Hcl111$2,619
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine55$2,418
Oxcarbazepine61$2,413
Carbamazepine ErCarbamazepine21$1,677
Perphenazine57$1,659
Prazosin Hcl52$1,456
Lamotrigine156$1,449
Duloxetine Hcl54$1,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$120$43,83232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 196 psychiatric/mental health providers in Rhode Island.

Other psychiatric/mental health in North Smithfield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →